Nathan Weinstein
Stock Analyst at Aegis Capital
(0.26)
# 4,339
Out of 5,031 analysts
61
Total ratings
13.33%
Success rate
-26.26%
Average return
Main Sectors:
Stocks Rated by Nathan Weinstein
Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
---|---|---|---|---|---|---|---|
EVGN Evogene | Maintains: Buy | $100 → $80 | $1.25 | +6,300.00% | 2 | Sep 12, 2022 | |
DRIO DarioHealth | Maintains: Buy | $400 → $300 | $13.24 | +2,165.86% | 6 | Aug 18, 2022 | |
VNRX VolitionRx | Maintains: Buy | $9 → $6 | $0.44 | +1,250.74% | 5 | Aug 15, 2022 | |
IMUX Immunic | Maintains: Buy | $40 → $35 | $0.80 | +4,273.36% | 2 | Aug 8, 2022 | |
STXS Stereotaxis | Initiates: Buy | $6 | $2.99 | +100.67% | 1 | Jul 12, 2022 | |
ORMP Oramed Pharmaceuticals | Maintains: Buy | $35 → $30 | $2.24 | +1,239.29% | 5 | May 16, 2022 | |
TRVI Trevi Therapeutics | Initiates: Buy | $10 | $10.36 | -3.47% | 1 | Mar 29, 2022 | |
MDWD MediWound | Maintains: Buy | $63 → $49 | $18.80 | +160.71% | 4 | Mar 21, 2022 | |
ENVB Enveric Biosciences | Downgrades: Hold | $5,250 → $150 | $0.76 | +19,660.24% | 2 | Mar 8, 2022 | |
CING Cingulate | Initiates: Buy | $2,160 | $3.70 | +58,278.38% | 1 | Jan 11, 2022 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $120 | $3.32 | +3,514.46% | 1 | Dec 7, 2021 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $9 → $10 | $1.10 | +809.09% | 2 | Nov 1, 2021 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $180 → $160 | $101.52 | +57.60% | 2 | Sep 22, 2021 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $60 → $56 | $34.69 | +61.43% | 2 | Sep 9, 2021 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $26 → $27 | $6.45 | +318.60% | 3 | Aug 17, 2021 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $40 → $35 | $0.75 | +4,538.22% | 4 | Jun 7, 2021 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $12 | $2.35 | +410.64% | 1 | Mar 22, 2021 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $75 | $9.49 | +690.31% | 1 | Jan 26, 2021 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $104 → $88 | $2.98 | +2,853.02% | 3 | Oct 19, 2020 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $180 | $4.05 | +4,344.44% | 1 | Oct 8, 2020 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $195 → $135 | $4.61 | +2,828.42% | 3 | Aug 3, 2020 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $14 | $6.06 | +131.02% | 1 | Jul 13, 2020 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $180 → $220 | $19.64 | +1,020.16% | 7 | May 4, 2020 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $8.5 | $4.10 | +107.32% | 1 | Mar 23, 2020 |
Evogene
Sep 12, 2022
Maintains: Buy
Price Target: $100 → $80
Current: $1.25
Upside: +6,300.00%
DarioHealth
Aug 18, 2022
Maintains: Buy
Price Target: $400 → $300
Current: $13.24
Upside: +2,165.86%
VolitionRx
Aug 15, 2022
Maintains: Buy
Price Target: $9 → $6
Current: $0.44
Upside: +1,250.74%
Immunic
Aug 8, 2022
Maintains: Buy
Price Target: $40 → $35
Current: $0.80
Upside: +4,273.36%
Stereotaxis
Jul 12, 2022
Initiates: Buy
Price Target: $6
Current: $2.99
Upside: +100.67%
Oramed Pharmaceuticals
May 16, 2022
Maintains: Buy
Price Target: $35 → $30
Current: $2.24
Upside: +1,239.29%
Trevi Therapeutics
Mar 29, 2022
Initiates: Buy
Price Target: $10
Current: $10.36
Upside: -3.47%
MediWound
Mar 21, 2022
Maintains: Buy
Price Target: $63 → $49
Current: $18.80
Upside: +160.71%
Enveric Biosciences
Mar 8, 2022
Downgrades: Hold
Price Target: $5,250 → $150
Current: $0.76
Upside: +19,660.24%
Cingulate
Jan 11, 2022
Initiates: Buy
Price Target: $2,160
Current: $3.70
Upside: +58,278.38%
Dec 7, 2021
Initiates: Buy
Price Target: $120
Current: $3.32
Upside: +3,514.46%
Nov 1, 2021
Maintains: Buy
Price Target: $9 → $10
Current: $1.10
Upside: +809.09%
Sep 22, 2021
Maintains: Buy
Price Target: $180 → $160
Current: $101.52
Upside: +57.60%
Sep 9, 2021
Maintains: Buy
Price Target: $60 → $56
Current: $34.69
Upside: +61.43%
Aug 17, 2021
Maintains: Buy
Price Target: $26 → $27
Current: $6.45
Upside: +318.60%
Jun 7, 2021
Maintains: Buy
Price Target: $40 → $35
Current: $0.75
Upside: +4,538.22%
Mar 22, 2021
Initiates: Buy
Price Target: $12
Current: $2.35
Upside: +410.64%
Jan 26, 2021
Initiates: Buy
Price Target: $75
Current: $9.49
Upside: +690.31%
Oct 19, 2020
Maintains: Buy
Price Target: $104 → $88
Current: $2.98
Upside: +2,853.02%
Oct 8, 2020
Initiates: Buy
Price Target: $180
Current: $4.05
Upside: +4,344.44%
Aug 3, 2020
Maintains: Buy
Price Target: $195 → $135
Current: $4.61
Upside: +2,828.42%
Jul 13, 2020
Initiates: Buy
Price Target: $14
Current: $6.06
Upside: +131.02%
May 4, 2020
Maintains: Buy
Price Target: $180 → $220
Current: $19.64
Upside: +1,020.16%
Mar 23, 2020
Initiates: Buy
Price Target: $8.5
Current: $4.10
Upside: +107.32%